USA - NASDAQ:AQB - US03842K3095 - Common Stock
The current stock price of AQB is 1.48 USD. In the past month the price decreased by -19.57%. In the past year, price increased by 28.7%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
AquaBounty Technologies, Inc. engages in the provision of land-based aquaculture services. The company is headquartered in Harvard, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2017-01-09. The Company’s technology advances in fish breeding, genetics, and health and nutrition. The company locates its land-based recirculating aquaculture system farms close to key consumption markets, which are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. Its land-based farms utilize Recirculating Aquaculture Systems, which are designed to prevent disease and include multiple levels of fish containment designed to protect wild fish populations. Recirculating Aquaculture Systems facilities provide water treatment technology, including the use of ozone, salt treatment and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens which might enter the system.
AQUABOUNTY TECHNOLOGIES
233 Ayer Road Suite 4, Suite 4
Harvard MASSACHUSETTS 01754 US
CEO: Sylvia A. Wulf
Employees: 4
Phone: 19786486000
AquaBounty Technologies, Inc. engages in the provision of land-based aquaculture services. The company is headquartered in Harvard, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2017-01-09. The Company’s technology advances in fish breeding, genetics, and health and nutrition. The company locates its land-based recirculating aquaculture system farms close to key consumption markets, which are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. Its land-based farms utilize Recirculating Aquaculture Systems, which are designed to prevent disease and include multiple levels of fish containment designed to protect wild fish populations. Recirculating Aquaculture Systems facilities provide water treatment technology, including the use of ozone, salt treatment and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens which might enter the system.
The current stock price of AQB is 1.48 USD. The price decreased by -3.9% in the last trading session.
AQB does not pay a dividend.
AQB has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AQUABOUNTY TECHNOLOGIES (AQB) operates in the Health Care sector and the Biotechnology industry.
AQUABOUNTY TECHNOLOGIES (AQB) has a market capitalization of 5.74M USD. This makes AQB a Nano Cap stock.
The outstanding short interest for AQUABOUNTY TECHNOLOGIES (AQB) is 4.6% of its float.
ChartMill assigns a technical rating of 6 / 10 to AQB. When comparing the yearly performance of all stocks, AQB is one of the better performing stocks in the market, outperforming 92.79% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to AQB. While AQB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AQB reported a non-GAAP Earnings per Share(EPS) of -35.61. The EPS decreased by -321.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -467.6% | ||
| ROE | -811.04% | ||
| Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 86.82% and a revenue growth 43.65% for AQB